过敏和免疫学市场 - 全球产业规模、份额、趋势、机会和预测（按治疗类型、过敏类型、分销管道、地区和竞争格局划分，2021-2031年）

全球过敏和免疫学市场预计将从 2025 年的 28.1 亿美元成长到 2031 年的 39.6 亿美元，复合年增长率为 5.88%。

该领域包括诊断工具、免疫疗法和药物干预，旨在治疗气喘、过敏、自体免疫疾病等免疫系统疾病。成长的主要驱动因素是全球范围内过敏性疾病的增加（由于都市化和环境污染）、医疗保健成本的上升以及人们对免疫健康的日益重视。

然而，研发和提供先进生物製药的高昂成本构成了一大障碍，可能限制发展中地区取得这些药物的机会。庞大的患者群体迫切需要扩充性且价格合理的解决方案。根据美国气喘和过敏基金会预测，到2024年，美国将有超过1亿人受到过敏性疾病的影响，这意味着市场对价格合理的治疗方案有着巨大的需求。

市场驱动因素

市场扩张的关键驱动因素是全球过敏性和自体免疫疾病发生率的上升，这促使人们从暂时缓解症状转向永续的疾病管理。快速的都市化和饮食习惯的改变等因素正在增加全球人口的易感性，这不再局限于西方国家，而已成为全球性的健康挑战。报导印证了这一扩张趋势。该文章估计，目前全球约有8%的儿童和10%的成年人受到食物过敏的影响，促使医疗保健系统优先考虑准确诊断和长期照护。

同时，针对免疫异常根本原因的标靶治疗，生物製药和免疫疗法的创新加速发展，正在改变这一领域。製药公司正大力投资单株抗体和脱敏疗法，例如，基因泰克公司在2024年2月宣布，其产品Zolia获得美国FDA核准，成为首个用于减少多重食物过敏患者反应的药物。这些进展的经济潜力巨大，艾伯维公司报告称，仅在2024年第三季度，其免疫学产品组合就创造了70.5亿美元的全球收入净额，凸显了下一代解决方案的强劲市场潜力。

市场挑战

研发和使用先进生物製药所需的高昂成本是全球过敏和免疫市场成长的主要障碍。由于研发投入大规模，这些复杂的治疗方法价格高昂，使得许多医疗系统和发展中国家的低收入患者难以负担。这种经济障碍阻碍了市场为日益增长的过敏患者群体提供充分的服务，导致相当一部分目标市场人群无法获得这些有效的治疗方法。

此外，过敏性疾病本身造成的经济负担也使得人们不愿意采用更高成本的治疗方法。根据美国气喘和过敏基金会2024年的数据，气喘每年对美国经济造成的损失超过820亿美元，凸显了医疗基础设施面临的巨大压力。因此，支付方往往不愿意补贴昂贵的生物製药疗法，由此造成的经济限制阻碍了这些先进免疫疗法的广泛应用。

市场趋势

市场正经历舌下免疫疗法（SLIT）的显着转变。其非侵入性和居家使用的便利性使其成为传统皮下注射疗法的理想替代方案。这种方法无需频繁就诊，提高了患者的依从性，尤其适合需要长期减敏治疗的上班族和儿童。製药公司正积极响应这项需求，扩大其标准化过敏治疗片剂的产品线。 ALK-Abello 在 2024 年年度报告中指出，截至 2025 年 2 月，其过敏免疫疗法片剂的全球销售额年增 24%，证实了口服製剂日益受到青睐。

此外，远端医疗平台的整合正在革新医疗服务模式，透过虚拟咨询和远距症状监测，实现慢性过敏症的管理。这一数位化趋势有助于解决农村地区专科医生短缺的问题，并支持混合护理模式，从而优化治疗通讯协定，无需患者亲自到诊。美国国立卫生研究院 (NIH) 于 2025 年 11 月发布的报告《远距过敏：远端医疗在过敏症患者管理中的潜力》强调了人们对这些工具日益增长的依赖性。报告发现，在受访的过敏症患者中，34% 的人曾使用远端医疗服务来管理他们的症状。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球过敏与免疫学市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（皮下免疫疗法（SCIT）、舌下免疫疗法（SLIT）、片剂、滴鼻剂）
  • 依过敏类型（过敏性鼻炎、过敏性气喘、其他过敏）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美过敏和免疫学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲过敏与免疫学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区过敏与免疫市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲过敏与免疫市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲过敏和免疫学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球过敏与免疫学市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AbbVie Inc.
• Stallergenes Greer PLC
• Allergy Therapeutics
• Sanofi SA
• Anacor Pharmaceuticals Inc.
• Novartis International AG
• AstraZeneca
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• GlaxoSmithKline PLC
• Mylan NV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Allergy and Immunology Market is projected to expand from USD 2.81 Billion in 2025 to USD 3.96 Billion by 2031, registering a CAGR of 5.88%. This sector includes diagnostic tools, immunotherapies, and pharmaceutical interventions aimed at treating immune system disorders such as asthma, hypersensitivities, and autoimmune diseases. Growth is largely propelled by the increasing prevalence of allergic conditions worldwide, driven by urbanization and environmental pollution, as well as rising healthcare spending and broader awareness of immune health.

However, the high costs involved in developing and delivering advanced biologic therapies present a significant obstacle, potentially limiting access in developing regions. The urgency for scalable and affordable solutions is highlighted by the sheer size of the patient population; according to the Asthma and Allergy Foundation of America, over 100 million people in the United States were affected by allergic conditions in 2024, demonstrating the vast scale of the market needing economical therapeutic options.

Market Driver

A primary catalyst for market expansion is the rising global incidence of allergic and autoimmune disorders, which is necessitating a transition from episodic symptom relief to sustained disease management. Factors such as rapid urbanization and shifting dietary habits have increased population sensitivity worldwide, making this a global health priority rather than just a Western issue. Highlighting this reach, an article in Frontiers in Nutrition from June 2024 titled 'Food allergies around the world' estimated that food allergies now impact approximately 8% of children and 10% of adults globally, prompting healthcare systems to prioritize accurate diagnostics and long-term care.

Simultaneously, the sector is being transformed by the acceleration of innovations in biologics and immunotherapies, which provide targeted treatments for the root causes of immune dysregulation. Pharmaceutical companies are heavily investing in monoclonal antibodies and desensitization therapies, evidenced by Genentech's February 2024 announcement that the U.S. FDA approved Xolair as the first medicine to reduce reactions in patients with multiple food allergies. The economic potential of these advancements is significant; AbbVie reported that its immunology portfolio generated $7.05 billion in global net revenues during the third quarter of 2024 alone, confirming the high market viability of next-generation solutions.

Market Challenge

The substantial expense required to develop and administer advanced biologic therapies stands as a major impediment to the growth of the Global Allergy and Immunology Market. The high pricing resulting from extensive research and development makes these complex treatments inaccessible for many healthcare systems in developing regions and patients with inadequate insurance. This financial barrier prevents the market from fully serving the expanding population of patients with allergic conditions, leaving a significant portion of the addressable market without access to these effective interventions.

Moreover, the existing economic burden of allergic diseases creates hesitation regarding the adoption of further high-cost treatments. Data from the Asthma and Allergy Foundation of America in 2024 indicated that the annual economic cost of asthma to the U.S. economy surpassed $82 billion, underscoring the strain on healthcare infrastructure. Consequently, payers are often reluctant to subsidize expensive biologic therapies, causing fiscal constraints that hinder the widespread expansion and adoption of these advanced immunological treatments.

Market Trends

The market is experiencing a notable shift toward Sublingual Immunotherapy (SLIT), which is becoming a preferred alternative to traditional subcutaneous injections due to its non-invasive nature and convenience for home use. This approach enhances patient compliance by removing the need for frequent clinic visits, making it highly suitable for working adults and children requiring long-term desensitization. Pharmaceutical firms are responding to this demand by increasing their offerings of standardized allergy tablets; ALK-Abello reported in its 'Annual Report 2024' that global sales of its allergy immunotherapy tablets rose by 24% in February 2025 compared to the prior year, confirming the growing preference for oral formulations.

In addition, the integration of telehealth platforms is revolutionizing care delivery by facilitating virtual consultations and remote symptom monitoring for chronic allergy management. This digital shift helps overcome specialist shortages in rural locations and supports hybrid care models that optimize treatment protocols without necessitating physical office visits. The growing reliance on these tools is evident in a November 2025 report by the National Institutes of Health, 'TeleAllergy: Potential of Telemedicine in Management of Patients With Allergies,' which noted that 34% of allergic patients surveyed had utilized telemedicine services to manage their conditions.

Key Market Players

• AbbVie Inc.
• Stallergenes Greer PLC
• Allergy Therapeutics
• Sanofi SA
• Anacor Pharmaceuticals Inc.
• Novartis International AG
• AstraZeneca
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• GlaxoSmithKline PLC
• Mylan N.V.

Report Scope

In this report, the Global Allergy And Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy And Immunology Market, By Treatment Type

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• Tablets
• Drops

Allergy And Immunology Market, By Allergy Type

• Allergic Rhinitis
• Allergic Asthma
• Other Allergies

Allergy And Immunology Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Allergy And Immunology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy And Immunology Market.

Available Customizations:

Global Allergy And Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy And Immunology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), Tablets, Drops)
  • 5.2.2. By Allergy Type (Allergic Rhinitis, Allergic Asthma, Other Allergies)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Allergy And Immunology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Allergy Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy And Immunology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Allergy Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Allergy And Immunology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Allergy Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Allergy And Immunology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Allergy Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Allergy And Immunology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Allergy Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Allergy And Immunology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Allergy Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Allergy And Immunology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Allergy Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Allergy And Immunology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Allergy Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Allergy And Immunology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Allergy Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Allergy And Immunology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Allergy Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Allergy And Immunology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Allergy Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Allergy And Immunology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Allergy Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Allergy And Immunology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Allergy Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Allergy And Immunology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Allergy Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Allergy And Immunology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Allergy Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Allergy And Immunology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Allergy Type
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Allergy And Immunology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Allergy Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Allergy And Immunology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Allergy Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Allergy And Immunology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Allergy Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Allergy And Immunology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Allergy Type
      • 9.3.3.2.3. By Distribution Channel

10. South America Allergy And Immunology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Allergy Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Allergy And Immunology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Allergy Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Allergy And Immunology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Allergy Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Allergy And Immunology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Allergy Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Allergy And Immunology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Stallergenes Greer PLC
• 15.3. Allergy Therapeutics
• 15.4. Sanofi SA
• 15.5. Anacor Pharmaceuticals Inc.
• 15.6. Novartis International AG
• 15.7. AstraZeneca
• 15.8. Merck KGaA
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. Johnson & Johnson
• 15.11. GlaxoSmithKline PLC
• 15.12. Mylan N.V.

16. Strategic Recommendations

17. About Us & Disclaimer